Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice

A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection

“…12,14 It has been demonstrated that vaccines based on a combination of three antigens can induce levels of protection similar to or even better than those induced by BCG in mice. 43,44 We therefore decided to combine three antigens in our study to get powerful protection against TB. Indeed, in line with the previous reports we were able to induce the M. tuberculosis specific protective response comparable to BCG.…”

“…9,10 For example, protein fusion vaccines constructed from two or three highly immunogenic, protective antigens, i.e.Ag85B and Esat6, were more efficacious than protein vaccines of the individual components alone. [11][12][13][14] Vaccines including combination of three plasmids encoding individual M. tuberculosis secreted proteins, 15 expression of multiple antigens with 2A or linker sequence, 16,17 and a synthetic scrambled antigen comprised of overlapping peptides from four M. tuberculosis proteins 18 also have been shown the great potency against TB in experimental model. About 170 M. tuberculosis antigens containing 800 human T cell epitopes have been identified in immune epitope databases.…”

Immunotherapeutic efficacy of recombinantMycobacterium smegmatisexpressing Ag85B–ESAT6 fusion protein against persistent tuberculosis infection in mice

“…The immunotherapeutic effect of AE-rMS alone in PTBI mice were accompanied by an increase in inflammatory responses in lung at the early stage, which could be due to the induction of strong immune-mediated inflammation by the Ag85B-ESAT6 fusion protein 41 and thus interfere with the therapeutic effect of AE-rMS. Early inflammatory responses were also observed in the combination therapy with AE-rMS and RI.…”

Protein expression of Myt272-3 recombinant clone and in silico prediction of a possible vaccine candidate against <i>Mycobacterium tuberculosis</i>

“…Efficient protection against tuberculosis is achieved in newborns by BCG, but unfortunately the vaccine does not prevent latent infection or reactivation of tuberculosis in adults [6]. In addition, BCG has shown protective efficacies in adult pulmonary tuberculosis, ranging from 0 to 80 per cent [7]. Identification of microbial components responsible for generation of immune responses is the first and most crucial step in the development of new vaccines [8].…”